Peer-reviewed veterinary case report
Enflicoxib is safe and effective for treating dog arthritis in 6 weeks
By Salichs, Marta et al.·Published in The Veterinary record·2022·Ecuphar Veterinaria SLU (Animalcare Group), Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, blind, multicentre clinical trial.
- Species:
- dog
Plain-English summary
A group of 242 dogs with osteoarthritis (a painful joint condition) were treated with enflicoxib, a new pain relief medication, to see how well it worked compared to a placebo and another medication called mavacoxib. After six weeks, 68% of the dogs receiving the higher dose of enflicoxib showed improvement in their pain levels, as reported by both veterinarians and their owners. The results were significantly better than those who received the placebo. Overall, enflicoxib was found to be effective and safe for managing pain in dogs with osteoarthritis.
People also search for: dog osteoarthritis treatment · enflicoxib for dogs · mavacoxib side effects · dog joint pain relief options
Abstract
BACKGROUND: Enflicoxib is a new COX-2 selective NSAID intended for the treatment of pain and inflammation associated with canine osteoarthritis. METHODS: A prospective, multisite, blinded, randomised, controlled, parallel-group field study was performed to determine the efficacy and safety of enflicoxib in canine osteoarthritis. A total of 242 dogs were randomised to receive enflicoxib at 4 or 2 mg/kg, mavacoxib at 2 mg/kg or placebo, orally. Enflicoxib and placebo were administered once weekly from day 0 to day 35. Mavacoxib was administered on D0 and day 14. Veterinarians assessed efficacy with a numerical rating scale and owners used the Canine Brief Pain Inventory. RESULTS: After 6 weeks, enflicoxib at 4 mg/kg showed the highest percentage of responders as assessed by the veterinarians (68%) and the owners (84%), followed by mavacoxib (62and 83%, respectively), and enflicoxib at 2 mg/kg (57 and 80%, respectively). All treatments reached statistical significance versus placebo, which obtained success rates of 37% and 53%, respectively. No differences in the incidence of adverse reactions were detected among the different groups. CONCLUSIONS: Enflicoxib administered weekly for 6 weeks, at 4 mg/kg PO with an initial loading dose of 8 mg/kg, is efficacious and safe for the treatment of canine osteoarthritis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34590318/